Viewing Study NCT06227156

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:36 PM
Ignite Modification Date: 2026-01-05 @ 5:36 PM
Study NCT ID: NCT06227156
Status: RECRUITING
Last Update Posted: 2024-05-23
First Post: 2024-01-17
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer
Sponsor: RemeGen Co., Ltd.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Castration-resistant Prostate Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Metastatic Castration-resistant prostate cancer. View
None HER2- expression View